2024
The development of lateral flow devices for urinary biomarkers to assess kidney health
D Souza S, Obeid W, Hernandez J, Hu D, Wen Y, Moledina D, Albert A, Gregg A, Wheeler A, Philbrook H, Parikh C. The development of lateral flow devices for urinary biomarkers to assess kidney health. Scientific Reports 2024, 14: 8516. PMID: 38609491, PMCID: PMC11014899, DOI: 10.1038/s41598-024-59104-5.Peer-Reviewed Original ResearchConceptsLateral flow deviceInterleukin-9Development of lateral flow devicesUrinary biomarkersDetection antibody concentrationSerum creatinine levelsKidney healthPaired antibodiesEnzyme Linked Immunosorbent AssayCreatinine levelsKidney injuryKidney functionOsteopontinImmunosorbent assayAntibody concentrationsMeasured biomarkersKidneyReal-time changesBiomarkers
2021
Secreted osteopontin from CD4+ T cells limits acute graft-versus-host disease
Aggarwal N, Deerhake ME, DiPalma D, Shahi SK, Gaggioli MR, Mangalam AK, Shinohara ML. Secreted osteopontin from CD4+ T cells limits acute graft-versus-host disease. Cell Reports 2021, 37: 110170. PMID: 34965439, PMCID: PMC8759344, DOI: 10.1016/j.celrep.2021.110170.Peer-Reviewed Original ResearchConceptsIntestinal epithelial cellsAcute GVHDHost diseaseMajor target organAcute graftBacteria AkkermansiaGastrointestinal pathologyMouse modelTarget organsFunction of osteopontinCD4Protective rolePotential biomarkersBeneficial effectsEpithelial cellsOPN isoformsMouse mutant modelsGVHDOsteopontinGraftCell deathDiseaseCellsMutant modelsAkkermansia
2015
Subtype-Specific Regeneration of Retinal Ganglion Cells following Axotomy: Effects of Osteopontin and mTOR Signaling
Duan X, Qiao M, Bei F, Kim IJ, He Z, Sanes JR. Subtype-Specific Regeneration of Retinal Ganglion Cells following Axotomy: Effects of Osteopontin and mTOR Signaling. Neuron 2015, 85: 1244-1256. PMID: 25754821, PMCID: PMC4391013, DOI: 10.1016/j.neuron.2015.02.017.Peer-Reviewed Original ResearchConceptsRetinal ganglion cellsDownregulation of PTENGanglion cellsInsulin-like growth factor-1Mouse retinal ganglion cellsAdministration of osteopontinAbility of RGCsSubtype-specific differencesGrowth factor-1Effect of osteopontinAxonal regenerationIGF-1High mTORSurvival rateΑRGCsMTOR pathwayPromising agentAxotomyMTOR signalingDistinct subsetsFactor 1Existence of subpopulationsInjuryOsteopontinDownregulation
2012
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population
Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, Rom W, Pass H, Donington J. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomarkers 2012, 12: 177-184. PMID: 23568008, PMCID: PMC3746829, DOI: 10.3233/cbm-130306.Peer-Reviewed Original ResearchConceptsIncident cancerPlasma osteopontinNon-small cell lung cancer careLung cancer careCase-control studySerial plasmaNSCLC patientsCT screeningSurveillance intervalsCancer careLung cancerPlasma levelsWilcoxon Signed Rank TestDisease statusCancerSigned Rank TestBenign nodulesSecreted phosphoproteinCTRank testOsteopontinEarly evidenceNSCLCPatientsNSCLCs
2011
Plasma Markers for Identifying Patients with Metastatic Melanoma
Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Plasma Markers for Identifying Patients with Metastatic Melanoma. Clinical Cancer Research 2011, 17: 2417-2425. PMID: 21487066, PMCID: PMC3415234, DOI: 10.1158/1078-0432.ccr-10-2402.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, CDBiomarkers, TumorCell Adhesion MoleculesEnzyme-Linked Immunosorbent AssayExtracellular Matrix ProteinsFemaleGlycoproteinsGrowth Differentiation Factor 15HumansIntercellular Adhesion Molecule-1L-Lactate DehydrogenaseMaleMelanomaMiddle AgedNeoplasm MetastasisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasm StagingNerve Growth FactorsPrognosisReproducibility of ResultsS100 Calcium Binding Protein beta SubunitS100 ProteinsSensitivity and SpecificityTissue Inhibitor of Metalloproteinase-1ConceptsGenome-wide gene expression dataGene expression dataHigh expression levelsLevels of proteinExpression dataExpression levelsProteinMelanoma cellsStage I/II diseaseEqual-sized trainingMarkersGenesDisease recurrencePlasma markersMetastatic melanomaTIMP-1Lactate dehydrogenaseCEACAMsStage I/II patientsDehydrogenaseOsteopontinStage IV diseaseStage IV patientsMetastatic melanoma patientsGender-matched patients
2000
Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks
O'Regan A, Nau G, Chupp G, Berman J. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Trends In Immunology 2000, 21: 475-478. PMID: 11071524, DOI: 10.1016/s0167-5699(00)01715-1.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply